Best‑Selling Cancer Drugs 2025: Top 10 Brands, Uses and MOA | Best selling cancer drugs | 2025 | iPharmaCenter

BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025

Rank	Brand	Revenues
1	Keytruda	$ 23.3 billion
2	Darzalex	$ 10.4 billion
3	Opdivo	$ 7.4 billion
4	Tagrisso	$ 5.4 billion
5	Imfinzi	$ 4.3 billion
6	Verzenio	$ 4.1 billion
7	Kisqali	$ 3.5 billion
8	Tecentriq	$ 3.3 billion
9	Ibrance	$ 3.0 billion
10	Perjeta	$ 2.9 billion

In 2025, global oncology revenues continue to be dominated by immune checkpoint inhibitors and targeted therapies, with Merck’s PD‑1 inhibitor Keytruda far ahead of the field. The top 10 cancer drugs by sales span solid tumors and hematologic malignancies and increasingly anchor multi‑drug regimens and earlier‑line treatment strategies.

Also read: Top pharmaceutical companies by revenues in 2025

1. Keytruda (pembrolizumab): PD‑1 checkpoint inhibitor

Keytruda is a humanized monoclonal antibody that blocks the programmed death‑1 (PD‑1) receptor on T cells, preventing interaction with PD‑L1/PD‑L2 and restoring antitumor immune activity. It has one of the broadest oncology labels, including unresectable or metastatic melanoma; multiple stages of non‑small cell lung cancer (NSCLC); small cell lung cancer; head and neck squamous cell carcinoma; classical Hodgkin lymphoma; urothelial carcinoma; MSI‑H/dMMR tumors; triple‑negative breast cancer; renal cell carcinoma; gastric and gastroesophageal junction cancers; cervical, endometrial and other solid tumors, across metastatic, neoadjuvant and adjuvant settings.

2. Darzalex (daratumumab): Anti‑CD38 monoclonal antibody

Darzalex is a human IgG1κ monoclonal antibody targeting CD38, a surface glycoprotein highly expressed on multiple myeloma cells. By binding CD38, it induces complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity and phagocytosis, and direct apoptosis. It is approved in combination backbones (for example with bortezomib, lenalidomide, pomalidomide) for newly diagnosed and relapsed/refractory multiple myeloma, in both transplant‑eligible and transplant‑ineligible patients, and in some high‑risk smouldering myeloma settings.

3. Opdivo (nivolumab): PD‑1 checkpoint inhibitor

Opdivo is a fully human IgG4 monoclonal antibody that blocks PD‑1, similar to Keytruda, re‑energizing exhausted T cells in the tumor microenvironment. Approved indications include unresectable or metastatic melanoma; adjuvant treatment of resected melanoma; a range of NSCLC and small cell lung cancer settings; renal cell carcinoma (alone or with ipilimumab); hepatocellular carcinoma; esophageal and gastric cancers; MSI‑H/dMMR colorectal cancer; head and neck cancer, mesothelioma and other solid tumors, often as mono‑ or combination immunotherapy.

Also read: EU clears Dupixent as first targeted CSU therapy in over a decade

4. Tagrisso (osimertinib): EGFR tyrosine kinase inhibitor

Tagrisso is a third‑generation, irreversible EGFR tyrosine kinase inhibitor that selectively targets sensitizing EGFR mutations and the T790M resistance mutation, with good CNS penetration. It is approved for first‑line treatment of metastatic EGFR‑mutated NSCLC, for T790M‑positive disease after progression on earlier EGFR TKIs, and as adjuvant therapy after tumor resection in patients with EGFR‑mutated NSCLC.

5. Imfinzi (durvalumab): PD‑L1 checkpoint inhibitor

Imfinzi is a human IgG1κ monoclonal antibody that binds programmed death‑ligand 1 (PD‑L1), blocking its interaction with PD‑1 and CD80 while sparing PD‑L2–PD‑1 signaling. Initially approved for unresectable stage III NSCLC after chemoradiation, it now has indications in extensive‑stage small cell lung cancer, biliary tract cancers, hepatocellular carcinoma and muscle‑invasive bladder cancer in combination regimens.

Also read: China NMPA Approves Pfizer’s Matazisimab (You Ruiting) for Routine Prophylaxis in Hemophilia Patients with Inhibitors

6. Verzenio (abemaciclib): CDK4/6 inhibitor

Verzenio is an oral small‑molecule inhibitor of cyclin‑dependent kinases 4 and 6, which regulate cell‑cycle progression from G1 to S phase. It is approved for hormone receptor‑positive, HER2‑negative breast cancer in both metastatic and early‑stage high‑risk settings, typically combined with endocrine therapy (such as aromatase inhibitors or fulvestrant) to delay progression and recurrence.

7. Kisqali (ribociclib): CDK4/6 inhibitor

Kisqali is another selective CDK4/6 inhibitor that halts cell‑cycle progression in Rb‑proficient tumor cells. Its label covers HR‑positive, HER2‑negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant in pre‑/perimenopausal and postmenopausal patients, with growing use in earlier‑line metastatic settings following strong overall‑survival data.

Also read: Novartis hopes its cancer drugs drive revenues until 2030

8. Tecentriq (atezolizumab): PD‑L1 checkpoint inhibitor

Tecentriq is a humanized IgG1 monoclonal antibody targeting PD‑L1, blocking its interactions with PD‑1 and B7.1 to restore antitumor T‑cell responses. It is approved for extensive‑stage small cell lung cancer, certain NSCLC settings, hepatocellular carcinoma, triple‑negative breast cancer, and urothelial carcinoma, often in combination with chemotherapy or targeted agents.

9. Ibrance (palbociclib): CDK4/6 inhibitor

Ibrance is a first‑in‑class oral CDK4/6 inhibitor that selectively inhibits cyclin‑D–dependent CDK4 and CDK6, leading to G1 cell‑cycle arrest. It is indicated for HR‑positive, HER2‑negative advanced or metastatic breast cancer in combination with aromatase inhibitors or fulvestrant, primarily in first‑line or subsequent‑line settings for postmenopausal women and men.

10. Perjeta (pertuzumab): HER2‑targeted monoclonal antibody

Perjeta is a humanized monoclonal antibody that binds a different epitope of the HER2 receptor than trastuzumab, blocking ligand‑dependent HER2 dimerization (especially HER2‑HER3), which is critical for downstream signaling. It is approved, in combination with trastuzumab and chemotherapy, for HER2‑positive metastatic breast cancer and for neoadjuvant and adjuvant treatment of early‑stage HER2‑positive breast cancer, forming a backbone of dual HER2 blockade.